68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies the use of 68Ga-PSMA-11 positron emission tomography (PET) in
diagnosing patients with prostate cancer that continues to grow despite the surgical removal
of the testes or medical intervention to block androgen production (castration resistant),
and has spread to other places in the body (metastatic). 68Ga- PSMA-11 is a new imaging agent
that may help get more detailed pictures of the tumor. This trial aims to see whether using
68Ga-PSMA-11 PET scans may help doctors learn more about where disease is located in the
body.
Phase:
Phase 2
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
Conquer Cancer Foundation Gateway for Cancer Research